Gilead Sciences: Strong HIV Growth Priced In, Diversification Still Limited Justifying Hold Rating

Maxim Group analyst Michael Okunewitch has maintained their neutral stance on GILD stock, giving a Hold rating on February 11.

Michael Okunewitch has given his Hold rating due to a combination of factors related to Gilead’s current performance and valuation. He notes that the company’s HIV franchise, led by Biktarvy, Descovy and the newer PrEP drug Yeztugo, is delivering solid growth and appears well insulated from competition, with additional upside from longer-acting formulations that should help sustain modest market expansion.

At the same time, he argues that much of this growth story is already embedded in the share price, as Gilead trades at a premium to large-cap biopharma peers and is near all-time highs. Oncology and liver disease products offer incremental opportunities, but he views these franchises as too small, for now, to transform the company’s reliance on HIV, which still represents the majority of sales, leading him to conclude that the current outlook is adequately reflected in the valuation.

In another report released on February 11, Goldman Sachs also maintained a Hold rating on the stock with a $125.00 price target.